Welcome to the e-CCO Library!

P333: Precise and unbiased infliximab dosing in patients with inflammatory bowel diseases using a multi-model averaging approach
Year: 2022
Source: ECCO'22
Authors: Kantasiripitak, W.(1);Outtier, A.(2,3);Thomas, D.(1);Kensert, A.(1);Wang, Z.(1);Sabino, J.(2,3);Wicha, S.G.(4);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1);
Created: Friday, 11 February 2022, 3:52 PM
P333: The baseline features of patients with newly diagnosed moderate-to-severe ulcerative colitis in Korea: A population-based cohort study (the MOSAIK cohort)
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.J. Oh1*, J.R. Moon1, C.K. Lee1, Y.M. Park1, S.N. Hong2, J.P. Im3, B.D. Ye4, J.M. Cha1, S.-A. Jung5, K.-M. Lee6, D.I. Park7, Y.T. Jeen8, Y.S. Park9, J.H. Cheon10, H.-S. Kim11, Y. Kim11, H.J. Kim1, H.J. Kim1, the IBD research group of the Korean Association for the Study of Intestinal Diseases

Created: Thursday, 21 February 2019, 9:14 AM
P334 Impact of disease duration on tofacitinib efficacy in patients with ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Travis1, I. Dotan2, S. Danese3, M. Chiorean4, J. Yamamoto-Furusho5, D. Ponce de Leon6, C. Su7, J. Paulissen8, E. Maller7, I. Modesto9, J.F. Colombel10

Created: Thursday, 30 January 2020, 10:12 AM
P334: Chromoendoscopy is superior to white light endoscopy for the detection of advanced colonic neoplasia in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. O. Kim*1,2, M. Chiorean2

Created: Friday, 22 February 2019, 9:41 AM
P334: Does the circadian clock have a role in the pathogenesis of inflammatory bowel disease (IBD)?
Year: 2018
Source: ECCO '18 Vienna
Authors:

Y. Weintraub1*, S. Cohen1, I. Dotan2,3, R. Tauman3,4, N. Chapnik5, O. Froy5

Created: Thursday, 21 February 2019, 9:14 AM
P334: Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort.
Year: 2022
Source: ECCO'22
Authors: Aparicio-Serrano, A.(1);Zamora Olaya, J.M.(1);Ortiz Chimbo, D.S.(1);Rodríguez Tirado, M.I.(1);Gómez Pérez, A.(1);Soto Escribano, P.(1);Marín Pedrosa, S.(1);Iglesias Flores, E.(1);Benítez, J.M.(1);
Created: Friday, 11 February 2022, 3:52 PM
P334: Evolution of a long-term follow-up cohort of Crohn’s disease with complex perianal fistula: from antibiotic to combined AZA and anti-TNF based treatment ending up clinical and radiological healing with or without stoma
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

Y. Erzin*, K. Ercaliskan, I. Hatemi, K. Atay, S. Bozcan, N. Demir, A. F. Celik

Created: Friday, 22 February 2019, 9:49 AM
P334: Medication adherence in diverse inner city pediatric patients with inflammatory bowel disease and comparison to physician perception of adherence
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ferreira J., Thomas S., Tomer G.

Created: Wednesday, 20 February 2019, 10:36 AM
P334: Respiratory Manifestations and Association Between Disease Activity in Patients with Inflammatory Bowel Disease in a Reference Center in Salvador, Bahia, Brazil.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fortes, F.(1,2)*;Gonçalves, J.(3);Nery, E.(4);Arenas, L.(4);Mota, J.(1);Pimentel, A.(1);Almeida, N.(5);Santos, A.M.(3);Surlo, V.(5);Santana, G.(4);
Created: Friday, 14 July 2023, 11:05 AM
P334: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the Ulcerative Colitis clinical programme
Year: 2021
Source: ECCO'21 Virtual
Authors: Ungaro, R.C.(1);Ciorba, M.A.(2);Rogler, G.(3);Sharara, A.I.(4);Sunna, N.(5);Connelly, S.B.(6);Mundayat, R.(7);Lawendy, N.(6);Panés, J.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P335 Treatment strategies after mucosal healing (MH) in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Sitibondo1, A. Viola1, G. Costantino1, A. Centritto1, A. Belvedere1, V. Pisana1, A. Abbruzzese1, A. Alibrandi2, W. Fries1

Created: Thursday, 30 January 2020, 10:12 AM
P335: A prospective multicentre “real-life” international validation study of the PICaSSO endoscopic scoring system against histologic scoring system to define mucosal healing in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Iacucci1,2*, M. Lazarev3, G.E. Tontini4, M. Daperno5, M. Goetz6, X. Gui7, V. Villanacci8, B.C. Lethebe9, M. Vecchi4, G. De Hertogh10, R. Mannan11, R. Hejmadi12, S. Smith2, U. Shivagi2, P. Bhandari13, S. Ghosh2, R. Kiesslich14, R. Bisschops15

Created: Thursday, 21 February 2019, 9:14 AM
P335: Cancer recurrence with immunosuppressive therapy in immune-mediated diseases: a systematic review and meta-analysis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Shelton*1, D. Laharie2, F. Scott3, R. Mamtani4, J. Lewis4, J.-F. Colombel5, A. Ananthakrishnan1

Created: Friday, 22 February 2019, 9:49 AM
P335: Impact of cancer therapy on the course of Inflammatory Bowel Disease (ONCOEII study of GETECCU)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Pérez Galindo, P.(1)*;Benítez, J.M.(2);Rubín de Célix, C.(3);Mesonero, F.(4);Castaño García, A.(5);García, M.J.(6);Vicuña, M.(7);Bernal, L.(8);Bertoletti, F.(9);Ramírez Castro, C.(10);Sánchez-Azofra, M.(11);Sánchez-Delgado, L.(12);Ponferrada, Á.(13);Tejido Sandoval, C.(14);Capilla, M.(15);Laredo de la Torre, V.(16);Diz-Lois, M.T.(17);Dueñas Sadornil, C.(18);García-Morales, N.(19);González-Vivo, M.(20);López-Cauce, B.(21);Melcarne, L.(22);Calviño-Suárez, C.(23);Lastiri González, E.(24);Ramírez de la Piscina, P.(25);Pérez-Gisbert, J.(3);Pérez Martínez, I.(5);Castro, B.(6);Cousillas, A.(26);Mañosa, M.(27);Carpio, D.(1);Barreiro-de Acosta, M.(23);
Created: Friday, 14 July 2023, 11:05 AM
P335: Long-term follow-up of switching from original infliximab to infliximab biosimilar: real-world data
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Guerra Veloz*1, M. Belvis Jimenez1, T. Valdes Delgado1, L. Castro Laria1, B. Maldonado Pérez1, A. Benítez Roldán1, R. Perea Amarillo1, V. Merino Bohorquez2, M. A. Calleja Hernandez2, A. Caunedo Álvarez1, A. Vilches Arenas3, F. Argüelles-Arias1

Created: Friday, 22 February 2019, 9:41 AM
P335: Prevalence and risk factors for non alcoholic fatty liver disease in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Iannone A.*1, Losurdo G.2, Shahini E.1, Albano F.1, La Fortezza R.F.1, Rizzi S.F.1, Contaldo A.1, Barone M.1, Ierardi E.1, Principi M.1, Di Leo A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P335: Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: A KASID multicenter cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Oh, K.(1);Hong, S.N.(2);Kim, E.S.(3);Na, S.Y.(4);Kang, S.B.(5);Koh, S.J.(6);Bang, K.B.(7);Jung, S.A.(8);Kim, K.O.(9);Choi, C.H.(10);Ye, B.D.(11);
Created: Wednesday, 2 June 2021, 4:12 PM
P335: Utility of Intestinal Ultrasound in Monitoring Disease Activity in Ulcerative Colitis Patients Treated with Biologics
Year: 2022
Source: ECCO'22
Authors: Tomašić, V.(1);Kralj, D.(1);Bišćanin, A.(1);Ćaćić, P.(1);Ogresta, D.(1);Dorosulić, Z.(1);Hrabar, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P336 Minimally invasive surgery is safe and feasible for luminal Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Nnaji, Y.F. Chin, O. Pujji, B. Wilkinson, S. Mohan, N.A. Yassin

Created: Thursday, 30 January 2020, 10:12 AM
P336: Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study
Year: 2021
Source: ECCO'21 Virtual
Authors: Dubinsky, M.C.(1);D’Haens, G.R.(2);Sandborn, W.J.(3);Ng, S.C.(4);Panés, J.(5);Su, C.(6);Lawendy, N.(6);Lazariciu, I.(7);Gardiner, S.(7);Mundayat, R.(7);Kulisek, N.(6);Modesto, I.(7);Torres, J.(8);
Created: Wednesday, 2 June 2021, 4:12 PM